Healthcare Legislation Tracker

Open comment periods

Have your say with federal health agencies

CMS, FDA, NIH, and other health agencies ask the public for input before they finalize rules and policies. Agency staff read every comment, and comments from patients and caregivers carry real weight. Each one below is open now. Anyone can comment, and you do not need a lawyer.

Featured for patients

• NIHNoticeCloses Oct 26, 2026

  Draft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participants

  NIH seeks public input on its proposed NIH Policy on Sharing Summary Level Study Results with Clinical Research Participants, including ways to promote and enable the research community to share summary level study results with clinical research participants.

  Submit a comment on Draft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participants (opens in a new tab)
• FDANoticeCloses Oct 26, 2026

  Patient-Focused Drug Development for Nonhealing Chronic Wounds; Public Meeting; Request for Comments

  The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Patient-Focused Drug Development for Nonhealing Chronic Wounds." The purpose of the public meeting is to obtain patient perspectives about the impact of nonhealing chronic wounds on daily life, patient views on treatment approaches, factors to consider when selecting a treatment, and what they consider when determining whether to participate in a clinical trial.

  Submit a comment on Patient-Focused Drug Development for Nonhealing Chronic Wounds; Public Meeting; Request for Comments (opens in a new tab)Read the notice for Patient-Focused Drug Development for Nonhealing Chronic Wounds; Public Meeting; Request for Comments (opens in a new tab)
• FDANoticeCloses Nov 9, 2026

  Improving Patient Access to Deceased Donor Islet Cells and Cell Products; Request for Information

  The Department of Health and Human Services (HHS) is opening a public docket to solicit input, supporting data, and comments to assist HHS as it considers how best to regulate deceased donor islet cells and/or deceased donor islet cell products for the treatment of Type 1 diabetes (T1D). The purpose of this information is to allow HHS agencies to better understand how best to regulate these therapies, including whether and how regulation could differ between isolated and otherwise unmodified deceased donor islet cells and deceased donor islet cell products. In this request for information, HHS will specify the type where appropriate or will refer to both types under the umbrella term of islet therapies. HHS seeks information on whether sufficient publicly available information exists to establish standards for how to transplant deceased donor islet cells and/or develop deceased donor islet cell products, as well as whether other publicly available data exist to support their safe and effective use. Additionally, HHS seeks input on the possibility of defining unmodified deceased donor islet cells as organs, which would allow the procurement, allocation, and transplantation of these cells to be performed in accordance with applicable Organ Procurement and Transplantation Network (OPTN) policy and regulated by HRSA. Doing so would require OPTN establishing appropriate standards for safety, effectiveness, quality and consistency of islet cell processing and isolation, and surveillance and policies regarding the training and experience of transplant surgeons and transplant physicians in designated pancreatic islet cell transplant programs.

  Submit a comment on Improving Patient Access to Deceased Donor Islet Cells and Cell Products; Request for Information (opens in a new tab)Read the notice for Improving Patient Access to Deceased Donor Islet Cells and Cell Products; Request for Information (opens in a new tab)
• FDANoticeCloses Nov 13, 2026

  Statistical Considerations for the Design of Rare Disease Clinical Investigations; Establishment of a Public Docket; Request for Information and Comments

  The Food and Drug Administration (FDA, the Agency, or we) is establishing a public docket to collect feedback on statistical considerations for rare disease clinical investigations. This docket is open in conjunction with a Rare disease Innovation, Science, and Exploration (RISE) Workshop on the same topic. Feedback is welcome both on the attached pre-read documents and on the content covered in the Workshop itself.

  Submit a comment on Statistical Considerations for the Design of Rare Disease Clinical Investigations; Establishment of a Public Docket; Request for Information and Comments (opens in a new tab)Read the notice for Statistical Considerations for the Design of Rare Disease Clinical Investigations; Establishment of a Public Docket; Request for Information and Comments (opens in a new tab)
• CMSProposed ruleCloses Nov 23, 2026

  Request for Information; Medicare Part D Reasonable and Relevant Pharmacy Contracting Standards

  This request for information (RFI) solicits input from interested parties for purposes of establishing standards for reasonable and relevant pharmacy contract terms and conditions under the Medicare prescription drug benefit. Section 6223(a) of the Consolidated Appropriations Act, 2026 (CAA, 2026) amends section 1860D- 4(b)(1)(A) of the Social Security Act (the Act) to require Part D plan sponsors to permit any pharmacy that meets standard contract terms and conditions under the plan to participate as a network pharmacy of the plan. Section 6223(a) of the CAA, 2026 further requires that, notwithstanding any other provision of law, for plan years beginning January 1, 2029, such standard contract terms and conditions offered by Part D plan sponsors must be reasonable and relevant according to standards established by the Secretary of the Department of Health and Human Services. Finally, section 6223(a) of the CAA, 2026 requires the Secretary to issue this RFI for purposes of establishing such standards.

  Submit a comment on Request for Information; Medicare Part D Reasonable and Relevant Pharmacy Contracting Standards (opens in a new tab)Read the notice for Request for Information; Medicare Part D Reasonable and Relevant Pharmacy Contracting Standards (opens in a new tab)

Listed from the Federal Register and updated daily. We filter out paperwork and industry-only notices. Listing a comment period does not mean the Foundation supports or opposes the proposal.